OTCMKTS:BRTXQ BioRestorative Therapies (BRTXQ) Stock Price, News & Analysis $1.69 +0.19 (+12.67%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$1.51▼$1.7050-Day Range$1.32▼$1.8952-Week Range$0.00▼$0.06Volume60,429 shsAverage Volume62.17 million shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get BioRestorative Therapies alerts: Email Address Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About BioRestorative Therapies Stock (OTCMKTS:BRTXQ)BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.Read More BRTXQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTXQ Stock News HeadlinesAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioRestorative Therapies Amid Strong Financials and Clinical ProgressAugust 12, 2024 | markets.businessinsider.comHere's what Wall Street expects from BioRestorative Therapies's earnings reportSeptember 16, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… May 3, 2024 | markets.businessinsider.comBioRestorative Therapies Inc Registered Shs hosts conference call for investorsMay 3, 2024 | markets.businessinsider.comBuy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth OpportunitiesApril 16, 2024 | markets.businessinsider.comWhy BioRestorative Therapies Is Rising In Pre-market?April 8, 2024 | msn.comBioRestorative Therapies partners with Galen Patient RecruitmentApril 3, 2024 | msn.comBioRestorative Therapies files to sell 2.51M shares of common stock for holdersSeptember 16, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… March 12, 2024 | forbes.com5 Best Affordable Online Therapy Options Of 2024February 6, 2024 | msn.comBioRestorative Therapies tumbles after private placementFebruary 5, 2024 | markets.businessinsider.comBioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc DiseaseJanuary 12, 2024 | morningstar.comBioRestorative Therapies Inc BRTXDecember 4, 2023 | money.usnews.comOccupational Therapy Assistant SalaryOctober 9, 2023 | nasdaq.comBioRestorative Therapies (FRA:9OF) Price Target Increased by 8.74% to 12.19September 1, 2023 | benzinga.comBioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are BuyingJuly 20, 2023 | benzinga.comBioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York StateJuly 11, 2023 | marketwatch.comBioRestorative Therapies Shares Lower Premarket on Stock Offering >BRTXSee More Headlines Receive BRTXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryHealthcare Current SymbolOTCMKTS:BRTXQ CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales25,190.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-2.49Miscellaneous Outstanding Shares1,639,626,000Free FloatN/AMarket Cap$2.77 billion OptionableNot Optionable Beta102.36 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark R. Weinreb M.S. (Age 67)Chairman, CEO & Pres Comp: $407.2kMr. Robert Paccasassi (Age 51)VP of Quality & Compliance Comp: $233.95kMr. Francisco J. Silva (Age 45)Chief Scientist and VP of R&D Comp: $310.5kDr. Wayne J. OlanClinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsPACS GroupNYSE:PACSOption Care HealthNASDAQ:OPCHSotera HealthNASDAQ:SHCSurgery PartnersNASDAQ:SGRYHims & Hers HealthNYSE:HIMSView All Competitors BRTXQ Stock Analysis - Frequently Asked Questions How have BRTXQ shares performed this year? BioRestorative Therapies' stock was trading at $1.7399 at the beginning of 2024. Since then, BRTXQ stock has decreased by 2.9% and is now trading at $1.69. View the best growth stocks for 2024 here. How do I buy shares of BioRestorative Therapies? Shares of BRTXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BRTXQ) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioRestorative Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.